Recent Research Analysts’ Ratings Changes for Bicycle Therapeutics (BCYC)

Several analysts have recently updated their ratings and price targets for Bicycle Therapeutics (NASDAQ: BCYC):

• 3/21/2026 – Bicycle Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/18/2026 – Bicycle Therapeutics had its price target lowered by Oppenheimer Holdings, Inc. from $44.00 to $36.00. They now have an “outperform” rating on the stock.
• 3/18/2026 – Bicycle Therapeutics had its price target lowered by Royal Bank Of Canada from $11.00 to $7.00. They now have a “sector perform” rating on the stock.
• 3/18/2026 – Bicycle Therapeutics had its price target lowered by Citizens Jmp from $12.00 to $8.00. They now have a “market outperform” rating on the stock.
• 3/18/2026 – Bicycle Therapeutics had its price target lowered by Needham & Company LLC from $24.00 to $15.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Bicycle Therapeutics was given a new $8.00 price target by Truist Financial Corporation.
• 3/17/2026 – Bicycle Therapeutics had its “sell” rating reaffirmed by Morgan Stanley. They now have a $13.00 price target on the stock.
• 2/17/2026 – Bicycle Therapeutics was upgraded by Jefferies Financial Group Inc. to “strong-buy”.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer directly owned 618,996 shares in the company, valued at $3,998,714.16. The trade was a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 38,029 shares of company stock valued at $251,966 in the last three months. 8.50% of the stock is owned by insiders.

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.